Biotech drugs have the potential to address unmet medical needs if physicians, patients and payers can accept their risk/benefit ratios and pricing, according to discussion at the 2007 Annual Meeting of the American Academy of Allergy, Asthma and Immunology in San Diego. In the asthma space, big pharma brands like Merck & Co. Inc.'s Singulair (montelukast sodium) and Schering Corp.'s Claritin (Ioratadine) already have been forced to share the spotlight with biotech drugs like Xolair (omalizumab, Genentech Inc. and Novartis AC), which brought Genentech $425 million in revenues in 2006. Yet Christopher Brightling, of the University of Leicester, UK, reported data from a survey of …
No comments:
Post a Comment